참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Cesium carbonate | HCID 10796 | — |
| 반응물 | 2-(Chloromethyl)-5-phenyl-1,3,4-oxadiazole | HCID 314941 | — |
| 반응물 | HCID 178509930 | HCID 178509930 | — |
| 용매 | Dimethylformamide | HCID 6228 | — |
| 생성물 | HCID 25109829 | HCID 25109829 | — |
반응 단계
3-chloro-5-[(5-chloro-1H-1,2,3-benzotriazol-4-yl)oxy]benzonitrile (100 mg, 0.328 mmol), cesium carbonate (107 mg, 0.328 mmol) and 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole (64 mg, 0.328 mmol) were combined and suspended in DMF (2 mL). After 16 hours, the reaction mixture was quenched with saturated aqueous ammonium chloride (1 mL) and extracted with EtOAc (2×25 mL). The combined organic fractions were evaporated under reduced pressure. The resulting residue was purified by reverse phase chromatography eluting with 30-95% MeCN/H2O+0.1% TFA. The product fractions were concentrated to yield the title compound. 1H NMR (DMSO-d6) δ 8.01 (d, J=9.1 Hz, 1H) 7.92 (d, J=8.6 Hz, 2H), 7.72 (m, 1H), 7.68 (m, 1H), 7.60 (m, 5H), 6.50 (s, 1H). HRMS (M+1)=463.0464.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07781454B2 |
|---|
| 출처 데이터셋 | uspto-grants-2010_08 |
|---|
| ORD ID | ord-0b02c66b78d14c25967218461506b397 |
|---|
| 출처 메모 | uspto-grants-2010_08 |
|---|